StockWatch
·

Suraksha Diagnostic Ltd Q2 FY27 Results

SURAKSHAQ2 FY27 Results
Filing
Result:Very Good· Market: Flat#Margin expansion#Record quarter
MetricValue (₹ Cr)Q2 FY26
Revenue99.0725.8%
Total Income100.5826.4%
Expenditure81.7021.0%
PBT18.8756.7%
Net Profit14.9569.4%
OPM35.14%4.51pp
NPM14.86%3.77pp
EPS2.8866.5%
View full financials

Clean, non-one-off PAT growth of ~67% YoY on strong 25.8% revenue growth with ~500bps EBITDA margin expansion, beating the company's own FY27 guidance a year ahead of schedule, marks a clear sector standout for a healthcare/diagnostics name.

Q2 FY-2027 RESULTS · SURAKSHA

Suraksha Diagnostic Q2FY27: consolidated PAT +67% YoY to ₹15 Cr, margins expand to ~36%

PAT +67.02% YoY · revenue +25.84% · margins expanding

10 Nov 2026 · 3 min read
Revenue

₹99.07 Cr

+25.84% YoY

PAT (consolidated)

₹14.95 Cr

+67.02% YoY

Net margin

14.86%

+3.8pp YoY

EPS

₹2.88

Suraksha Diagnostic's consolidated PAT attributable to owners rose 67.0% YoY to ₹15.01 Cr (₹8.99 Cr a year ago) on consolidated revenue from operations of ₹99.07 Cr, up 25.8% YoY and 13.0% QoQ; EPS climbed to ₹2.88 from ₹1.73. Standalone told a similar story — revenue ₹94.53 Cr (+23.9% YoY) and PAT ₹15.30 Cr. There is no exceptional item on either side of the comparison, so the YoY jump is a clean, like-for-like print rather than a base-effect artefact. Profit outgrew revenue because the EBITDA margin expanded by roughly 500 basis points, from an estimated ~31% in the year-ago quarter to ~36% now, as employee costs and other operating expenses fell as a share of revenue — the operating leverage from new-center maturation and cost efficiencies that management flagged on the May 2026 call. That expansion came despite finance costs rising 74.3% YoY (₹4.84 Cr vs ₹2.78 Cr) and depreciation up 24.3% YoY (₹12.61 Cr vs ₹10.14 Cr), both consequences of Ind AS 116 lease capitalisation tied to the network build-out; the topline and cost-ratio gains were large enough to absorb this and still lift PBT margin.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹99.07 Cr—+25.8%
Expenses₹81.7 Cr—+21%
PAT₹14.95 Cr+15.39%+67.02%
Net margin14.86%—+3.8pp
EPS₹2.88—+66.5%

Against management's own FY27 guidance from the May 2026 concall — revenue growth around 15% and EBITDA margin stabilising near 33% (medium-term target 35%, long-term 38-39%) — this quarter is running well ahead: revenue grew 25.8% YoY and the margin is already tracking close to the medium-term goal and within sight of the long-term band, roughly a year earlier than the glide path implied. We found no analyst consensus or brokerage preview specifically for this quarter (small-cap, thin coverage), so vsStreet is unknown; this is read purely against the company's own stated guidance, which it has beaten on both lines. Capex discipline also looks on track: H1FY27 consolidated capex (purchase of PP&E/intangibles) was ₹33.59 Cr, roughly 48% of the ₹70 Cr FY27 network-expansion guide for West Bengal, Bihar, Jharkhand and Tripura, consistent with a similar run rate in H2.

₹
236.78269.78302.78335.77368.77353.208-0708-3109-2310-1611-09
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹353.2, up 11.7% over the past month of trading.

₹ Cr
05.5811.1616.747.17Q4 FY25rev ₹65 Cr9.18Q1 FY26rev ₹73 Cr8.83Q2 FY26rev ₹79 Cr8.14Q3 FY26rev ₹76 Cr6.16Q4 FY26rev ₹81 Cr14.95Q2 FY27rev ₹99 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.

What management guided (1 FY-2026 call)
Management provided strong guidance for FY27, projecting revenue growth around 15% while committing to over-delivering. They expect EBITDA margins to stabilize around 33% in FY27, with a medium-term target of 35% and a long-term outlook of 38-39%, driven by operating leverage from new center maturation and cost efficie

— This quarter: beat

Two other developments sit alongside the print: Dinesh Gupta was appointed CFO in August 2026, mid-way through this reporting half, and the six consolidated subsidiaries (Suraksha Speciality, Suraksha Radiology, Suraksha Advanced Radiology, AIIR, Fetomat Wellness, Suraksha Salvia) remain collectively loss-making, with non-controlling interests at -₹0.06 Cr this quarter versus -₹0.16 Cr in Q1FY27 — narrowing, but still the reason consolidated PAT sits slightly below standalone. No separate management press release was available with this filing to cross-check against the Board's own framing of the quarter.

  • W1

    Whether the ~36% EBITDA margin holds or eases as new centers (non-consolidated subsidiaries included) keep ramping — management's own medium-term target is 35%, long-term 38-39%

  • W2

    H2FY27 capex pace against the ₹70 Cr full-year guide, with ₹33.59 Cr (48%) already spent in H1

  • W3

    Narrowing of subsidiary losses (NCI -₹0.06 Cr this quarter vs -₹0.16 Cr in Q1FY27) toward consolidated-standalone PAT convergence

Clean digital tables, both standalone and consolidated arithmetic ties out exactly; figures converted from ₹ Lakh (÷100). No exceptional items in either period or the year-ago comparative — impairment-loss line is immaterial (-₹0.09 Cr this quarter, ₹0.20 Cr a year ago), so no adjusted-growth add-back applies. Consolidated PAT (owners) of ₹15.01 Cr trails standalone PAT of ₹15.30 Cr by ~1.9% on subsidiary losses (NCI -₹0.06 Cr) — not a material basis divergence.

Informational and educational content only. Not investment advice.